The present and future of combination chemotherapy in bladder cancer

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 9, 2002, Pages 32-39

  Culine, Stephane ^a,b  

^a Center Val d'Aurel   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PEMETREXED; VINBLASTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; FUTUROLOGY; GROWTH INHIBITION; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; TUMOR GROWTH; UROTHELIUM;

EID: 0036310027     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34271     Document Type: Conference Paper

References (65)

1. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium
2. M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urothelium
3. M-VAC (methotrexate, vinbastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience
4. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
5. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
6. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
7. Association between patient characteristics and treatment history, and toxicity associated with methotrexate, vinblastine, adriamycin and cisplatin (MVAC) for advanced urothelial cancer
8. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy
9. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
10. Metastatic urothelial cancer: Evaluation of prognostic factors and change in prognosis during the last twenty years
11. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
12. Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer
13. Randomized phase III trial of high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for the Research and Treatment of Cancer Protocol no. 30924
14. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why
15. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial
16. SWOG 8710 (INT-0080): Randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer
17. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum
18. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
19. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
20. Gemcitabine monotherapy as 2nd-line treatment in cisplatin refractory transitional cell carcinoma
21. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium. A phase Il trial of the Eastern Cooperative Oncology Group
22. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter
23. Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy
24. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
25. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma
26. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer: Results of a phase II study in non-chemotherapy-pretreated patients
27. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel
28. A phase II study of the multi-targeted antifolate, MTA, in patients with advanced transitional cell carcinoma of the bladder
29. Weekly gemcitabine and cisplatin combination chemotherapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
30. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
31. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
32. Palliative chemotherapy with gemcitabine (Gem) and carboplatin (CBDCA) in advanced transitional cell carcinoma of the urothelium (ATCCU). Preliminary results
33. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer
34. Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma (UC)
35. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group study
36. Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): A clinical phase II study
37. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen
38. Paclitaxel plus carboplatin in advanced urothelial carcinoma: Improving the therapeutic index
39. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urorhelial carcinoma
40. Phase II study of Taxol (paclitaxel) and carboplatin in patients with advanced transitional-cell carcinoma of the urothelium. Preliminary results
41. Phase II trial of paclitaxel (P) plus carboplatin (C) in advanced urothelial tract cancer (UTC)
42. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract
43. Carboplatin and paclitaxel (Carbo/Tax) for advanced transitional cell carcinoma (TCC) of the urothelium
44. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study
45. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group
46. Phase II study of docetaxel (D) and cisplatin (CDDP) in advanced urothelial cancer: Preliminary results
47. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
48. Paclitaxel, cisplatin and methotrexate combination chemotherapy in the treatment of refractory urothelial malignancies
49. Phase I/I trial of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma
50. Paclitaxel (T) combination chemotherapy in untreated and in resistant stage IV transitional cell carcinoma (TCC) of the urinary bladder: A retrospective study
51. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
52. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract. Final report of a phase II trial evaluating two dosing schedules
53. Phase I evaluation of sequential doxorubicin + gemcitabine then ifosfamide + paclitaxel + cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract
54. Sequential doxorubicin/gemcitabine (AG) and ifosfamide, paclitaxel, and cisplatin (ITP) chemotherapy (AG-ITP) in patients (Pts) with metastatic or locally advanced transitional cell carcinoma (TCC) of the urothelium
55. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
56. Gemcitabine, cisplatin and paclitaxel (GPT) in advanced transitional bladder cancer. Is there a schedule-dependent clinical effect?
57. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. Updated results
58. Phase I/II Study of docetaxel (D), gemcitabine (G), carboplatin (C) in poor prognosis and previously treated patients (Pts) with urothelial carcinoma (UTC)
59. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial
60. A phase II trial of ifosfamide + paclitaxel (IT) in advanced transitional cell carcinoma of the urothelium
61. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network
62. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2W): A multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC)
63. A phase II evaluation of gemcitabine plus docetaxel as therapy for advanced transitional cell carcinoma of the urothelial tract
64. Phase II evaluation of gemcitabine (GEM) and epirubicin (EPI) in advanced bladder cancer
65. Gemcitabine and vinorelbine combination in patients older than 70 years or unresponsive to a cisplatin chemotherapy in advanced bladder cancer